Lv1
90 积分 2025-05-13 加入
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
19天前
已完结
Differential effects of vedolizumab and etrolizumab-s on UC CD4+ and CD8+ T cell trafficking in the inflamed gut in vivo
1个月前
已关闭
Comparison of in vivo T cell homing to the inflamed gut with the etrolizumab surrogate antibody FIB504 and vedolizumab in a humanised mouse model
1个月前
已关闭
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins
1个月前
已完结
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
3个月前
已完结
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
4个月前
已完结
Clinical determinants and long-term survival in heart failure with supra-normal ejection fraction. Insights from LECRA-HF registry
4个月前
已完结
Clinical determinants and long-term survival in heart failure with supra-normal ejection fraction. Insights from LECRA-HF registry
4个月前
已完结
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
4个月前
已完结
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction Primary Results of the EMBARK-HFpEF Trial
5个月前
已完结
皖公网安备34019202002308
